Rush CEO Omar Lateef will step down to pursue a national health equity agenda, Crain's reports. His departure leaves a key leadership moment for the Chicago system.

Northwestern's Project DRIVE provided software Apple used to let Vision Pro wearers steer powered wheelchairs with their eyes. The feature rolls out initially with limited drive‑system support.

Automate 2026 turns McCormick Place into a robot showcase, with a NVIDIA-sponsored Humanoid Pavilion and hundreds of live demos from major automation vendors. The four-day event highlights how AI is changing industrial robotics.

Thousands of Xfinity customers reported service interruptions Monday; outage trackers logged a sharp spike while engineers worked to restore service.

AbbVie is reportedly buying Apogee Therapeutics for about $11 billion, adding a late‑stage eczema drug and deepening its immunology pipeline in North Chicago.

A Chicago team built a linked‑exoskeleton rehab that lets therapists guide stroke survivors' movements in real time. Early tests showed gains in walking metrics and strong patient engagement.

Chicago cybersecurity experts warn that AI chats and third‑party apps can expose private conversations. Here’s what happened and what to stop sharing now.

Teva completed its purchase of Chicago‑based Emalex, paying $700M up front and positioning ecopipam—an effective Phase 3 Tourette candidate—for an NDA in the second half of 2026.

A Northwestern professor and four other diabetes researchers were escorted from the ADA Scientific Sessions in New Orleans after distributing reprints of a Diabetes Care editorial critical of proposed NIH policy changes.

Edward Hines Jr. VA Hospital in suburban Chicago has begun enrolling veterans in a supervised psilocybin-assisted therapy trial for treatment‑resistant PTSD.

Chicago buyout firm Thoma Bravo agreed to take Limerick‑based Kneat private in an all‑cash deal valuing the life‑sciences validation software maker at about C$650M.

FDA found Bacillus cereus and other quality lapses at Medline's Waukegan drug plant; the agency ordered independent risk assessments and remediation timelines.

Chicago’s Tempus won FDA clearance to run its xT CDx test without matched normal samples, a label expansion the company says will broaden use and affect reimbursement.